Professor | Bai Shan Jiang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Bai Shan Jiang
Contact Information	Email: baishan_jiang[at]whu.edu.cn
Language ability	Chinese, English
Province	Hubei

Upload Avatar (500 x 500)

Name

Bai Shan Jiang

Contact Information

Email: baishan_jiang[at]whu.edu.cn

Language ability

Chinese, English

Province

Hubei

University/Lab Affiliation and Title	Wuhan University
Faculty	Immunology and Metabolion
Academic Background & Achievements	2001-2005 Bachelor in Pharmaceutical Engineering, Xiangtan University 2005-2011 Ph.D. in Medicinal Chemistry, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Work Experience	2011-2015 Assistant Researcher, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences 2015-2019 Postdoc, Dana-Farber Cancer Institute, Harvard Medical School 2019-2022 Research Scientist, Dana-Farber Cancer Institute, Harvard Medical School 2022-Present Professor, Medical Research Institute, Wuhan University

University/Lab Affiliation and Title

Wuhan University

Faculty

Immunology and Metabolion

Academic Background & Achievements

2001-2005 Bachelor in Pharmaceutical Engineering, Xiangtan University
2005-2011 Ph.D. in Medicinal Chemistry, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences

Work Experience

2011-2015 Assistant Researcher, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
2015-2019 Postdoc, Dana-Farber Cancer Institute, Harvard Medical School
2019-2022 Research Scientist, Dana-Farber Cancer Institute, Harvard Medical School
2022-Present Professor, Medical Research Institute, Wuhan University

Areas of Focus	Small molecule inhibitors Protein degraders
Publications	Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability, Ye, M.; Fang, Y.; Chen, L.; Song, Z.; Bao, Q.; Wang, F.; Huang, H.; Xu, J.; Wang, Z.; Xiao, R.; Han, M.; Gao, S.; Liu, H.; Jiang, B.; Qing, G. , 2024 Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity, Koide, E.; Mohardt, M. L.; Doctor, Z. M.; Yang, A.; Hao, M.; Donovan, K. A.; Kuismi, C. C.; Nelson, A. J.; Abell, K.; Aguiar, M.; Che, J.; Stokes, M. P.; Zhang, T.; Aguirre, A. J.; Fischer, E. S.; Gray, N. S.; Jiang, B. ; Nabet, B. , 2023 ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas, Jiang, B.; Weinstock, D. M.; Donovan, K. A.; Sun, H. W.; Wolfe, A.; Amaka, S.; Donaldson, N. L.; Wu, G.; Jiang, Y.; Wilcox, R. A.; Fischer, E. S.; Gray, N. S.; Wu, W., 2023 Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions, Gao, Y.#; Jiang, B. #; Kim, H. #; Berberich, M. J.; Che, J.; Donovan, K. A.; Hatcher, J. M.; Huerta, F.; Kwiatkowski, N. P.; Liu, Y.; Liuni, P. P.; Metivier, R. J.; Murali, V. K.; Nowak, R. P.; Zhang, T.; Fischer, E. S.; Gray, N. S.; Jones, L. H., 2023 INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors, Li, Q. #; Jiang, B. #; Guo, J. #; Shao, H.; Del Priore, I. S.; Chang, Q.; Kudo, R.; Li, Z.; Razavi, P.; Liu, B.; Boghossian, A. S.; Rees, M. G.; Ronan, M. M.; Roth, J. A.; Donovan, K. A.; Palafox, M.; Reis-Filho, J. S.; de Stanchina, E.; Fischer, E. S.; Rosen, N.; Serra, V.; Koff, A.; Chodera, J. D.; Gray, N. S.; Chandarlapaty, S., 2022 Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma, Jiang, B. #; Gao, Y. #; Che, J.; Lu, W.; Kaltheuner, I. H.; Dries, R.; Kalocsay, M.; Berberich, M. J.; Jiang, J.; You, I.; Kwiatkowski, N.; Riching, K. M.; Daniels, D. L.; Sorger, P. K.; Geyer, M.; Zhang, T.; Gray, N. S., 2021 Discovery and resistance mechanism of a selective CDK12 degrader, Jiang, B. #; Gao, Y. #; Che, J.; Lu, W.; Kaltheuner, I. H.; Dries, R.; Kalocsay, M.; Berberich, M. J.; Jiang, J.; You, I.; Kwiatkowski, N.; Riching, K. M.; Daniels, D. L.; Sorger, P. K.; Geyer, M.; Zhang, T.; Gray, N. S., 2021 Discovery of Covalent MKK4/7 Dual Inhibitor, Jiang, J. #; Jiang, B. #; He, Z.; Ficarro, S. B.; Che, J.; Marto, J. A.; Gao, Y.; Zhang, T.; Gray, N. S., 2020 Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6, Jiang, B. #; Wang, E. S. #; Donovan, K. A.; Liang, Y.; Fischer, E. S.; Zhang, T.; Gray, N. S., 2019 Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML, Brand, M. #; Jiang, B. S. #; Bauer, S.; Donovan, K. A.; Liang, Y. K.; Wang, E. S.; Nowak, R. P.; Yuan, J. T. C.; Zhang, T. H.; Kwiatkowski, N.; Müller, A. C.; Fischer, E. S.; Gray, N. S.; Winter, G. E., 2019

Areas of Focus

Small molecule inhibitors
Protein degraders

Publications

Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability, Ye, M.; Fang, Y.; Chen, L.; Song, Z.; Bao, Q.; Wang, F.; Huang, H.; Xu, J.; Wang, Z.; Xiao, R.; Han, M.; Gao, S.; Liu, H.; Jiang, B.*; Qing, G. *, 2024
Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity, Koide, E.; Mohardt, M. L.; Doctor, Z. M.; Yang, A.; Hao, M.; Donovan, K. A.; Kuismi, C. C.; Nelson, A. J.; Abell, K.; Aguiar, M.; Che, J.; Stokes, M. P.; Zhang, T.; Aguirre, A. J.; Fischer, E. S.; Gray, N. S.; Jiang, B. *; Nabet, B. *, 2023
ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas, Jiang, B.; Weinstock, D. M.; Donovan, K. A.; Sun, H. W.; Wolfe, A.; Amaka, S.; Donaldson, N. L.; Wu, G.; Jiang, Y.; Wilcox, R. A.; Fischer, E. S.; Gray, N. S.; Wu, W., 2023
Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions, Gao, Y.#; Jiang, B. #; Kim, H. #; Berberich, M. J.; Che, J.; Donovan, K. A.; Hatcher, J. M.; Huerta, F.; Kwiatkowski, N. P.; Liu, Y.; Liuni, P. P.; Metivier, R. J.; Murali, V. K.; Nowak, R. P.; Zhang, T.; Fischer, E. S.; Gray, N. S.; Jones, L. H., 2023
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors, Li, Q. #; Jiang, B. #; Guo, J. #; Shao, H.; Del Priore, I. S.; Chang, Q.; Kudo, R.; Li, Z.; Razavi, P.; Liu, B.; Boghossian, A. S.; Rees, M. G.; Ronan, M. M.; Roth, J. A.; Donovan, K. A.; Palafox, M.; Reis-Filho, J. S.; de Stanchina, E.; Fischer, E. S.; Rosen, N.; Serra, V.; Koff, A.; Chodera, J. D.; Gray, N. S.; Chandarlapaty, S., 2022
Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma, Jiang, B. #; Gao, Y. #; Che, J.; Lu, W.; Kaltheuner, I. H.; Dries, R.; Kalocsay, M.; Berberich, M. J.; Jiang, J.; You, I.; Kwiatkowski, N.; Riching, K. M.; Daniels, D. L.; Sorger, P. K.; Geyer, M.; Zhang, T.; Gray, N. S., 2021
Discovery and resistance mechanism of a selective CDK12 degrader, Jiang, B. #; Gao, Y. #; Che, J.; Lu, W.; Kaltheuner, I. H.; Dries, R.; Kalocsay, M.; Berberich, M. J.; Jiang, J.; You, I.; Kwiatkowski, N.; Riching, K. M.; Daniels, D. L.; Sorger, P. K.; Geyer, M.; Zhang, T.; Gray, N. S., 2021
Discovery of Covalent MKK4/7 Dual Inhibitor, Jiang, J. #; Jiang, B. #; He, Z.; Ficarro, S. B.; Che, J.; Marto, J. A.; Gao, Y.; Zhang, T.; Gray, N. S., 2020
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6, Jiang, B. #; Wang, E. S. #; Donovan, K. A.; Liang, Y.; Fischer, E. S.; Zhang, T.; Gray, N. S., 2019
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML, Brand, M. #; Jiang, B. S. #; Bauer, S.; Donovan, K. A.; Liang, Y. K.; Wang, E. S.; Nowak, R. P.; Yuan, J. T. C.; Zhang, T. H.; Kwiatkowski, N.; Müller, A. C.; Fischer, E. S.; Gray, N. S.; Winter, G. E., 2019

Small Molecule Inhibitors Protein Degraders Dual-Function Molecular Glue Protein Stabilizers Synthesis Proteomics Biological Function

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us